Get the Stockscreener App
18.47
0.05%
0.010
After Hours:
18.47
Rocket Pharmaceuticals Inc stock is traded at $18.47, with a volume of 866.83K.
It is up +0.05% in the last 24 hours and down -2.02% over the past month.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.
See More
Previous Close:
$18.46
Open:
$18.22
24h Volume:
866.83K
Relative Volume:
1.04
Market Cap:
$1.68B
Revenue:
-
Net Income/Loss:
$-249.31M
P/E Ratio:
-5.5801
EPS:
-3.31
Net Cash Flow:
$-209.70M
1W Performance:
-6.62%
1M Performance:
-2.02%
6M Performance:
-31.44%
1Y Performance:
-9.86%
1-Day Range:
$18.14
$18.87
1-Week Range:
$17.42
$19.87
52-Week Range:
$16.55
$32.52
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
Name
Rocket Pharmaceuticals Inc
Sector
Industry
Phone
646-440-9100
Address
350 FIFTH AVENUE, NEW YORK, NY
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-01-23 | Initiated | Morgan Stanley | Overweight |
| Nov-08-22 | Initiated | Canaccord Genuity | Buy |
| Nov-01-22 | Initiated | BTIG Research | Buy |
| Jul-08-22 | Initiated | Raymond James | Outperform |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Mar-02-21 | Initiated | Stifel | Buy |
| Feb-18-21 | Initiated | Needham | Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Dec-08-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-02-20 | Initiated | JP Morgan | Overweight |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| Nov-06-19 | Initiated | Chardan Capital Markets | Buy |
| Sep-26-19 | Initiated | Piper Jaffray | Overweight |
| Apr-23-19 | Initiated | Robert W. Baird | Outperform |
| Mar-15-19 | Initiated | BofA/Merrill | Buy |
| Feb-05-19 | Initiated | Oppenheimer | Outperform |
| Sep-13-18 | Initiated | Ladenburg Thalmann | Buy |
| Jul-10-18 | Initiated | William Blair | Outperform |
View All
Rocket Pharmaceuticals Inc Stock (RCKT) Latest News
Metric Analysis: Rocket Pharmaceuticals Inc (RCKT)’s Key Ratios in the Limelight - The Dwinnex
Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Rating Reaffirmed by Canaccord Genuity Group - MarketBeat
Perceptive Advisors LLC Sells 554,471 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
Rocket Pharmaceuticals' SWOT analysis: gene therapy stock faces market size concerns - Investing.com UK
Rocket Pharmaceuticals Inc [RCKT] Records 50-Day SMA of $20.33 - Knox Daily
Maverick Capital Ltd. Purchases 40,000 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
Profund Advisors LLC Decreases Stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price Up 3.9% - Defense World
A significant driver of top-line growth: Rocket Pharmaceuticals Inc (RCKT) - SETE News
Rocket Pharmaceuticals Inc (RCKT) Stock: The Story of a 52-Week Stock Range - The InvestChronicle
Logos Global Management LP Has $7.54 Million Stock Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Down 5.7% - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Trading Down 5.7% - MarketBeat
Insider’s View: Deciphering Rocket Pharmaceuticals Inc (RCKT)’s Financial Health Through Ratios - The Dwinnex
Should investors be concerned about Rocket Pharmaceuticals Inc (RCKT)? - US Post News
RCKT (Rocket Pharmaceuticals Inc) may reap gains as insiders became active recently - Knox Daily
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Sold by Victory Capital Management Inc. - MarketBeat
Will Rocket Pharmaceuticals (NASDAQ:RCKT) Spend Its Cash Wisely? - Simply Wall St
Blair William & Co. IL Has $3.07 Million Holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
(RCKT) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Rocket Pharmaceuticals Inc [RCKT] insider makes an insider purchase of 1,064 shares worth 19688.0. - Knox Daily
Rocket Stock Down More Than 30% in Past Six Months: Here's Why - MSN
Contrasting Rocket Pharmaceuticals (NASDAQ:RCKT) & Guardion Health Sciences (NASDAQ:GHSI) - Defense World
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Rocket: Danon Disease Treatment Program Should Carry The Tide Until Regulatory Moves - Seeking Alpha
Renaissance Technologies LLC Raises Stock Holdings in Rocket Companies, Inc. (NYSE:RKT) - Defense World
Rocket Companies Inc [RKT] Shares Jump Approximately 120.76% Over the Year - Knox Daily
Canaccord maintains Buy rating on Rocket Pharma, with consistent price target - Investing.com Canada
Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Down 3.5% - Defense World
Rocket Companies stock soars to 52-week high of $21.3 - Investing.com
Rocket Cos. Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Rocket Companies (NYSE:RKT) Sets New 1-Year High at $21.38 - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price Down 3.5% - MarketBeat
Rocket Pharmaceuticals Inc (RCKT) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - The InvestChronicle
Rocket Pharmaceuticals Inc (RCKT) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Canaccord maintains Buy rating on Rocket Pharma, with consistent price target - Investing.com UK
RCKT Completes Enrollment in Rare Heart Disease Study, Stock Rises - Zacks Investment Research
Did Rocket Companies Inc (RKT) perform well in the last session? - US Post News
Rhythm Pharmaceuticals initiated with a Buy at H.C. Wainwright - TipRanks
Rocket Pharmaceuticals’ (RCKT) Buy Rating Reaffirmed at Needham & Company LLC - Defense World
Rocket Pharmaceuticals completes enrollment for Danon disease trial - Investing.com
Morgan Stanley maintains Overweight rating on Rocket Pharmaceuticals stock By Investing.com - Investing.com Canada
Rocket Pharmaceuticals (NASDAQ:RCKT) Trading 6.4% Higher - MarketBeat
Rocket Cos. Inc. stock outperforms competitors on strong trading day - MarketWatch
Ratio Review: Analyzing Rocket Pharmaceuticals Inc (RCKT)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Rocket Pharma stock gains on trial update (NASDAQ:RCKT) - Seeking Alpha
Perhaps timely catching Rocket Companies Inc (RKT) would be a good idea - SETE News
Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Rating Reaffirmed by Needham & Company LLC - MarketBeat
Rocket Companies: Sky-High Hopes, Grounded Reality (NYSE:RKT) - Seeking Alpha
Rocket Pharmaceuticals completes enrollment for Danon disease trial - Investing.com India
Rocket Pharmaceuticals: All patients enrolled in RP-A501 study to treat Danon - TipRanks
Rocket Pharmaceuticals Inc Stock (RCKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):